FDA Oncologic Drugs Advisory Committee (ODAC) Recommends KEYTRUDA® (pembrolizumab) for the Treatment of Certain Patients with High-Risk, Non-Muscle Invasive Bladder Cancer (NMIBC)
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) voted 9-4 in favor of recommending KEYTRUDA, Merck’s anti-PD-1 therapy, for the treatment of certain patients with high-risk, non-muscle invasive bladder cancer (NMIBC).
Language:
English
Contact:
Media:
Pamela Eisele
(267) 305-3558
Claire Gillespie
(267) 305-0932
Investors:
Peter Dannenbaum
(908) 740-1037
Michael DeCarbo
(908) 740-1807
Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck
